CYTRX PROVIDES 2006 UPDATE ON RNAI-BASED DRUG DISCOVERY PROGRAMS

CytRx Corporation today reported substantial progress in its drug discovery programs aimed at using its proprietary RNA interference (RNAi) technologies to develop novel molecular medicines to treat obesity and type 2 diabetes. "During the past year, CytRx-sponsored research programs have discovered and validated approximately 30 new type 2 diabetes and obesity drug targets through the use of our high throughput functional RNAi screening platform.
Yahoo News